Cytokinetics, IncorporatedCYTKNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank38
3Y CAGR-50.9%
5Y CAGR-35.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-50.9%/yr
Quarterly compound
5Y CAGR
-35.5%/yr
Recent deceleration
Percentile
P38
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 2.32% |
| Q3 2025 | -11.84% |
| Q2 2025 | 12.73% |
| Q1 2025 | 6.63% |
| Q4 2024 | 10.66% |
| Q3 2024 | 6.30% |
| Q2 2024 | -2.42% |
| Q1 2024 | -4.01% |
| Q4 2023 | 2.96% |
| Q3 2023 | -0.80% |
| Q2 2023 | 4.75% |
| Q1 2023 | 5.87% |
| Q4 2022 | 19.58% |
| Q3 2022 | 9.82% |
| Q2 2022 | 24.36% |
| Q1 2022 | 5.60% |
| Q4 2021 | -10.19% |
| Q3 2021 | 32.91% |
| Q2 2021 | 15.47% |
| Q1 2021 | 8.01% |
| Q4 2020 | 20.74% |
| Q3 2020 | 11.07% |
| Q2 2020 | 0.24% |
| Q1 2020 | 18.57% |
| Q4 2019 | -9.37% |
| Q3 2019 | -15.77% |
| Q2 2019 | 2.00% |
| Q1 2019 | 1.15% |
| Q4 2018 | 8.82% |
| Q3 2018 | -0.88% |
| Q2 2018 | -2.50% |
| Q1 2018 | -15.68% |
| Q4 2017 | 5.23% |
| Q3 2017 | 25.94% |
| Q2 2017 | 2.70% |
| Q1 2017 | 2.73% |
| Q4 2016 | 5.10% |
| Q3 2016 | 83.74% |
| Q2 2016 | -28.16% |
| Q1 2016 | 2.15% |